A new long-acting reversible contraception (LARC) method offering protection from unplanned pregnancy for up to five years has been launched by Bayer. Kyleena releases a low daily dose of levonorgestrel in a five-year intrauterine system, using a small T-body and narrow insertion tube.

Lars Bruening, Bayer’s CEO and UK head of pharma, says: “Kyleena provides women with an additional, reliable and reversible contraceptive option.”


Market monitor: July

Product updates from Training Matters.

The guru is back

The Deep Relief guru is returning to TV for six weeks from mid-September in an attempt to extend the success of the memo...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Training Matters's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.